AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05719909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: 8 sessions of web-based cognitive training
Study NCT05719909 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: 8 sessions of web-based sham training
Study NCT06194461 — intervention group
Intervention type: BIOLOGICAL
Intervention: AZD0754
Description: Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729.
Study NCT05297825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Omnivore diet
Description: Healthy omnivore diet.
Study NCT05478447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: whole-body vibration, and tendon vibrations will be applied to the human body
Study NCT06506877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of Cognitive Risk Calculator (RC) and Brief Assessment of Cognitive Health (BACH)
Description: Enrolled providers will have access to two cognitive screening tools during the active phase. The first tool is a Cognitive Risk-Calculator (RC), integrated into the Electronic Health Record, to help providers identify patients who are at high risk of exhibiting cognitive decline. The second tool is a computerized cognitive screening tool, the Brief Assessment of Cognitive Health (BACH), which patients complete independently. Results are automatically entered into the patient's medical record, along with patient-specific flags for concerns about depression and/or sleep disorder. The purpose of these tools is to facilitate cognitive screening and treatment for factors that may be contributing to cognitive decline.
Study NCT06176508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10374
Description: Administered orally QD for 16 weeks
Study NCT06176508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10374-matched placebo tablets
Description: Administered orally QD for 16 weeks
Study NCT06176508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5Mg Tab,Oral
Description: Administered orally BID for 16 weeks
Study NCT03518333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection of adipose derived cells into penis
Description: Injection of Icellator-derived cells
Study NCT05855668 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT
Description: 12 weeks of group CBT for AUD or CUD
Study NCT05596916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High frequency of stretching exercise
Description: After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 5 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment.
Study NCT05596916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency of stretching exercise
Description: After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 3 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment.
Study NCT06018766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM-001
Description: LAM-001 administered via dry powder inhaler
Study NCT06018766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via dry powder inhaler
Study NCT06442215 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Collection of preoperative demographic, clinical, and radiological variables from patients who meet the inclusion criteria in order to identify possible risk factors for suboptimal surgical treatment
Study NCT06303895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation training
Description: Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week.
Study NCT06303895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation training
Description: Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week.
Study NCT06303895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing rehabilitation training
Description: Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced.
Study NCT06303895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing rehabilitation training
Description: Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced.
Study NCT06303895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Description: The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula).
Study NCT06394453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enteral feeding with mother milk or human donor breast milk
Description: The experimental group will start enteral feeding with mother milk or human donor breast milk if mother milk is not accesible during the first day of therapeutic hypothermia.
Study NCT06177093 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR Linac delivered Radiotherapy
Description: All radiotherapy will be delivered on the MR-linac. The whole prostate will receive 30 Gy in 5 fractions and the dominant lesion plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.
Study NCT00313976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Description: 250 micrograms every other day, subcutaneously for 104 weeks
Study NCT00313976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Description: 2x250 micrograms every other day, subcutaneously for 104 weeks
Study NCT04986280 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]PSMA-1007
Description: PSMA PET/CT using the intervention.
Study NCT04887389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride varnish
Description: Nano Silver Fluoride(5%) is a new experimental formulation containing silver nanoparticles, chitosan and fluoride combines preventive and antimicrobial properties. It is a yellow solution and safe to be used in humans
Study NCT04887389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nano-hydroxyapatite varnish
Description: nano-hydroxyapatite (10%) has antibacterial effect, higher solubility, surface energy and bioactivity and its structure is similar to dental apatite.
Study NCT04887389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium Fluoride Varnish
Description: Fluoride varnish (5%) applied every six months is effective in preventing caries in the primary and permanent dentition of children and adolescents
Study NCT06013436 — intervention group
Intervention type: DRUG
Intervention: Autologous serum tears combined with 0.05% cyclosporin eye drop
Description: All patients administrated autologous serum tears twelve times daily（per hour） and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.
Study NCT06198855 — intervention group
Intervention type: DEVICE
Intervention: QMon-20 device
Description: Automatic Blood pressure measurement with QMon-20 device in the waiting room for 20 minutes every 5 minutes.
Study NCT04454736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amateur Group Singing
Description: 45-minute singing session led by a professional choirmaster without a therapeutic background once a week
Study NCT04454736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Group Singing
Description: 120-minute singing session led by a professional choirmaster without a therapeutic background three times a week. Assessments take place twice a week.
Study NCT05951712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone 150mg
Description: Impact of simethicone on the mucosal visibility of stomach and duodenum
Study NCT05951712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetyl cysteine 600mg
Description: Impact of N Acetyl cysteine on the mucosal visibility of stomach and duodenum
Study NCT05951712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone 150mg plus N Acetyl cysteine 600 mg
Description: Impact of simethicone plus N Acetyl cysteine on the mucosal visibility of stomach and duodenum
Study NCT05091840 — intervention group
Intervention type: OTHER
Intervention: oximetry monitoring
Description: monitoring oximetry in both groups using the INVOS™ system 5100C Oximeter
Study NCT05951712 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Impact of water on the mucosal visibility of stomach and duodenum
Study NCT05370469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensus Smartwatch Application
Description: Sensus is capable of administering ecological momentary assessments (EMAs) on a schedule, randomly, or using sensor-triggers. In this way, Sensus will capture both active (patient-initiated) and passive data streams from native smartphone sensors. Passive streams may include, but are not limited to, GPS, accelerometer, gyroscope, and pedometer data. Participants will be able to log data such as their activity, symptoms and medication adherence via user-initiated surveys within the Sensus app. Sensus will also prompt users to record their medication adherence, symptoms, or activity. This will be done either at fixed intervals (e.g., three times daily) or whenever the onboard sensors detect potential changes in a user's physiological state (e.g., shaking / moving around).
Study NCT05370469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RX Cap
Description: The RXCap medication event monitoring device will be used to collect data on participant adherence to their TKI medication. A small computer chip is included in the top of a pill bottle. When the cap is taken off of the pill bottle by turning it or unscrewing it, the cap records the time and date that it was removed.
Study NCT05370469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Sense
Description: The Fitbit Sense smartwatch will be used to collect data including steps, calories burned, total distance travelled, sleep (e.g. time spent sleeping and quality of sleep), flights of stairs climbed, active minutes, exercise (e.g. minutes spent exercising at various intensities), and average heart rate.
Study NCT05370469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Electronic and paper surveys will be administered throughout the study.
Study NCT04817293 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire SSD-12 and EQ5D5L
Study NCT04817293 — intervention group
Intervention type: OTHER
Intervention: medical consultation
Description: Medical consultation during the visit with data collection
Study NCT05019287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic human menstrual blood stem cells secretome
Description: This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.
Study NCT05019287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline injection
Description: Intravenous saline injection in addition to standard care
Study NCT05529966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NGENUITY
Description: Device for 3-D viewing during placement of micro-stent placement.
Study NCT05529966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional microscope
Description: Device for stereoscopic viewing during placement of micro-stent placement.
Study NCT03063190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: patients will receive vitamin D supplementation according to guidelines
Study NCT03063190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: patients will receive placebo oral tablets
Study NCT05223387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axiom TL REG
Description: Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis
Study NCT05223387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axiom BL REG
Description: Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis
Study NCT04814771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] TS-142
Description: Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq \[14C\]TS-142 as an oral solution
Study NCT06632366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual Dysfunction in the Postpartum Period
Description: The experimental group will receive mindfulness-based self-compassion training. The control group will not receive any intervention.
Study NCT05774886 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Implantable Microdevice (IMD)
Description: * Small, implantable device with 30 reservoirs for drug and drug combinations.~* Placement of 2 microdevices into tumor will be performed via needle, percutaneously, and guided by interventional radiologic techniques.~* Drugs include all or a subset of the following: Doxorubicin, Paclitaxel, Carboplatin, Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat, Panobinostat, Olaparib, Capecitabine, Sacituzumab govitecan, Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin (combination), Carboplatin + paclitaxel (combination), Doxorubicin + cyclophosphamide + pembrolizumab (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin + Pembrolizumab (combination), Paclitaxel + atezolizumab (combination), Paclitaxel + pembrolizumab (combination), Carboplatin + gemcitabine + pembrolizumab (combination), Carboplatin + paclitaxel + pembrolizumab (combination), Trastuzumab deruxtecan
Study NCT04378296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teledermatology
Description: The experimental group will be made up of dermatological patients monitored asynchronously.
Study NCT05226611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counterstrain
Description: Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
Study NCT06386705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSN084
Description: TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Study NCT05546073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced point-of-care technology
Description: The intervention consists of:~* focused lung ultrasound scan(FLUS)~* venous blood samples for leucocytes with 5-part differential count, creatinin, sodium, potassium, urea
Study NCT04726059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation
Description: Therapeutic TSCS will be delivered during ABT using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). Stimulation will involve charge balanced monophasic rectangular waveforms with 1.0-ms pulses, administered at 30 Hz, with a carrier frequency of 10 kHz and a current ranging from 10 to 130 mA.
Study NCT04726059 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM (low-intensity) Transcutaneous Spinal Cord Stimulation
Description: Ineffective stimulation will be administered at the same anatomical location as therapeutic TSCS.
Study NCT04726059 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Activity-Based Therapy
Description: Using BWSTT, all participants (both arms) will train 3 times per week for 12 weeks with a target to reach 45 minutes of gait training in each session.~For gait training, the level of body weight support and speed of walking will be adjusted to allow the person to bear as much weight as possible while maintaining proper stance limb kinematics.
Study NCT04726059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity-Based Therapy
Description: Using BWSTT, all participants (both arms) will train 3 times per week for 12 weeks with a target to reach 45 minutes of gait training in each session.~For gait training, the level of body weight support and speed of walking will be adjusted to allow the person to bear as much weight as possible while maintaining proper stance limb kinematics.
Study NCT05628207 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.
Study NCT05628207 — intervention group
Intervention type: OTHER
Intervention: Observational-control
Description: There is no intervention, the hospitals will not use the CDS system.
Study NCT03859921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: Progesterone
Study NCT03859921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with appearance similar to Dydrogesterone
Study NCT05152810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation sessions
Description: * 10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~* 2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase
Study NCT05152810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation sessions
Description: * 10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~* 2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase